CLAIMS:

1. A compound of Formula I



Formula I

, or a pharmaceutically acceptable salt thereof, wherein:

X^1 is NR^{x1}, O or S;

X^2 is N or CR^{x2};

X^3 is O, NR^7, CR^4R^8, C(O), $S(O)_t$, $C=CR^4R^0$ or $C=NR^4$;

X^4 and X^6 are independently O or S;

X^5 is O, S or NR^0;

L is a bond or C_{1-6}alkylene;

L^1 is a bond, C_{1-6}alkylene, O, NR^c, C(O), $C(O)NR^c$, $S(O)_t$ or $S(O)_tNR^c$;

R^{x1} and R^{x2} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, haloC_{1-6} alkyl and C_{3-6} monocycloalkyl;

R^a, R^b and R^c are independently selected for each occurrence from the group consisting of hydrogen, C_{1-6} alkyl, haloC_{1-6} alkyl and C_{3-6} monocycloalkyl;

R^d is hydrogen, OH, C_{1-6}alkyl or C_{1-6} alkoxy;

R^0, R^6, R^8 and R^{11} are independently selected for each occurrence from the group consisting of hydrogen, halogen, OH, CN, NO_2, oxo, $R^dN=$, hydrazino, formyl, azido, silyl, siloxy, HOC(O)-, R^aR^bN-, $R^aR^bNS(O)_t$-, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} monocycloalkyl, haloC_{1-6} alkyl, hydroxyC_{1-6} alkyl-, $R^aR^bNC_{1-6}$ alkyl-, $HOC(O)C_{1-6}$ alkyl-, $R^aR^bNC_{1-6}$ alkylNR^c-, C_{1-6} alkylNR^aC_{1-6} alkylNR^c-, C_{1-6} alkoxy, haloC_{1-6} alkoxy, hydroxyC_{1-6} alkoxy-, $R^aR^bNC_{1-6}$ alkoxy-, C_{1-6}alkoxyC_{1-6} alkyl-, haloC_{1-6} alkoxyC_{1-6} alkyl-, $R^aR^bNC(O)$-, C_{1-6} alkyl$C(O)$-, C_{1-6} alkoxy$C(O)$-, C_{1-6} alkyl$C(O)O$-, C_{1-6} alkyl$S(O)_q$-, C_{1-6} alkyl$S(O)_tNR^c$-, C_{1-6} alkyl$S(O)_tC_{1-6}$ alkyl-, C_{1-6} alkyl$S(O)_tNR^aC_{1-6}$ alkyl-, C_{3-6} cycloalkyl$S(O)_tC_{1-6}$ alkyl-, C_{1-6} alkyl$C(O)C_{1-6}$ alkyl-, and C_{1-6} alkyl$C(O)OC_{1-6}$ alkyl-;

R^{0a} is independently selected for each occurrence from the group consisting of hydrogen, halogen, OH, CN, NO_2, R^aR^bN-, C_{1-6}alkyl and haloC_{1-6}alkyl;

R^1 is a phenyl, naphthyl, C_{3-6} monocycloalkyl, C_{3-6} monoheterocycloalkyl, or 5-6 membered monocyclic heteroaryl, wherein: the phenyl, C_{3-6} monocycloalkyl, C_{3-6} monoheterocycloalkyl, or 5-6 membered monocyclic heteroaryl is optionally substituted with one, two, or three independently selected R^{11} groups;

R^2 is hydrogen, halogen, R^aR^bN, C_{1-6} alkyl, haloC_{1-6} alkyl, C_{3-6} monocycloalkyl or C_{1-6} alkoxy;

R^3 is selected from the group consisting of:



;

R^4 is R^5, R^6 or R^5-L^1-;

or R^4 and R^8 together with the carbon atom to which they are attached form a



or group;

R^{4a} is hydrogen or C_{1-6}alkyl;

R^{4b} is R^5, R^{5a}, R^6 or R^5-L^1-;

R^5 is selected from the group consisting of:






and

;

R^{5a} is ;

R^{5b} is 

or ;

R^{6a} is hydrogen or C_{1-6}alkyl;

R^7 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxyC_{1-6} alkyl-, $NR^aR^bC(O)$-, $R^{7a}C(O)$-, C_{1-6} alkyloxyC(O)-, C_{1-6} alkyl$S(O)_q$- or C_{1-6} haloalkyl$S(O)_q$-;

R^{7a} is C_{1-6}alkyl or C_{3-6}monocycloalkyl;

q, r, t, and w are independently selected for each occurrence from 0, 1 and 2; and

v is independently selected for each occurrence from 0, 1, 2 and 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X^1 is NR^{x1}, X^2 is N, and R^{x1} is hydrogen or methyl.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R^{x1} is methyl.

4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein is L is a bond.

5. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein L^1 is a bond.

6. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R^2 is R^aR^bN.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein R^2 is NH_2.

8. The compound according to any one of Claims 1-7, or a pharmaceutically acceptable salt thereof, wherein: R^1 is ;

R^{11} is independently selected for each occurrence from the group consisting of halogen, CN, $C_{1\text{-}6}$ alkyl and halo$C_{1\text{-}6}$ alkyl; and

z1 is 0, 1, 2 or 3.

9. The compound of Claim 8, or a pharmaceutically acceptable salt thereof, wherein for each occurrence R^{11} is independently selected from the group consisting of F, Cl, Br and I.

10. The compound of Claim 9, or a pharmaceutically acceptable salt thereof, wherein R^1 is .

11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

14. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein R^3 is .

17. The compound of claim 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R^4 and R^8 together with the carbon atom to which they are attached form a



or


group.

18. The compound of claim 15 or 16, or a pharmaceutically acceptable salt thereof, wherein R^3 is


.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R^3 is


.

20. The compound of claim 18 or 19, or a pharmaceutically acceptable salt thereof, wherein R^6 is $C_{1\text{-}6}$ alkyl$S(O)_tC_{1\text{-}6}$ alkyl- or $C_{1\text{-}6}$ alkyl$S(O)_tNR^aC_{1\text{-}6}$ alkyl-.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein R^6 is $C_{1\text{-}6}$ alkyl$S(O)_tC_{1\text{-}6}$ alkyl-, and t is 1 or 2.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein t is 2.

23. The compound according to any one of claims 18-22, or a pharmaceutically acceptable salt thereof, wherein R^8 is hydrogen, OH or $C_{1\text{-}6}$ alkoxy.

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R^8 is OH.

25. A pharmaceutical composition comprising the compound according to any one of claims 1-24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

26. Use of a compound according to any one of claims 1-24, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Hepatitis B (HBV) infection in a subject in need thereof.

27. Use of a therapeutically effective amount of pharmaceutical composition of claim 25 in the manufacture of a medicament for treating Hepatitis B (HBV) infection in a subject in need thereof.